10-Q: Cardiff Lexington Q2: Revenue Up, Losses Soar
Quarterly Report
Cardiff Lexington Corporation reported a significant increase in revenue for Q2 2025, but also a substantial rise in net loss driven by soaring interest expenses and ongoing liquidity challenges.
Summary
- Revenue for the six months ended June 30, 2025, increased by 50.37% to $5,704,574, up from $3,793,775 in the prior year period.
- Gross profit rose by 72.26% to $3,535,792 for the six months ended June 30, 2025, compared to $2,052,611 in the same period last year, with gross margin improving from 54.10% to 61.98%.
- Income from operations significantly increased to $1,153,611 for the six months ended June 30, 2025, from $59,509 in the prior year.
- Net loss for the six months ended June 30, 2025, widened by 304.44% to $(1,677,172) from $(414,689) in the comparable period.
- Interest expense dramatically increased to $2,829,186 for the six months ended June 30, 2025, compared to $417,616 in the prior year, primarily due to increased fees on the line of credit.
- Cash balance decreased to $559,715 as of June 30, 2025, from $1,188,185 at December 31, 2024.
- Accounts receivable, net, increased to $19,193,419 as of June 30, 2025, from $15,934,490 at December 31, 2024.
- The company's line of credit balance increased to $12,690,193 as of June 30, 2025, from $8,645,991 at December 31, 2024.
- An accumulated deficit of $75,125,710 was reported as of June 30, 2025, raising substantial doubt about the company's ability to continue as a going concern.
- The company's healthcare segment (Nova) generated all revenue and significantly contributed to operating income, while the real estate segment (Edge View) reported an operating loss.
Sentiment
Score: 2
Explanation: The sentiment is very negative due to a substantial increase in net loss, soaring interest expenses, a significant decrease in cash, and an explicit 'going concern' warning. While revenue and gross profit improved, the underlying financial health and liquidity position have deteriorated significantly, indicating severe operational and financial challenges.
Positives
- Total revenue increased by 50.37% for the six months ended June 30, 2025, reaching $5,704,574.
- Gross profit improved by 72.26% to $3,535,792, with gross margin increasing from 54.10% to 61.98%.
- Income from operations saw a substantial increase to $1,153,611 for the six months ended June 30, 2025, from $59,509 in the prior year.
- The settlement realization rate on gross billed charges for the healthcare segment improved slightly to 43.18% as of June 30, 2025, from 41.80% in the prior year period.
Negatives
- Net loss for the six months ended June 30, 2025, significantly widened to $(1,677,172), a 304.44% increase from $(414,689) in the prior year.
- Interest expense surged to $2,829,186 for the six months ended June 30, 2025, compared to $417,616 in the prior year, primarily due to increased fees on the line of credit.
- Cash balance decreased by $628,470 to $559,715 as of June 30, 2025.
- The company's accumulated deficit grew to $75,125,710 as of June 30, 2025, indicating sustained historical losses.
- The line of credit balance increased by over $4 million to $12,690,193, increasing financial leverage.
- The company continues to operate under a going concern warning due to recurring operating losses and an accumulated deficit, dependent on future capital infusions.
Risks
- Ability to continue as a going concern is in substantial doubt due to recurring operating losses and accumulated deficit.
- Inability to obtain sufficient additional capital from debt or equity transactions or from operations in the necessary timeframe or on acceptable terms.
- Potential for significant dilution to stockholders from the sale of additional equity securities.
- Increased debt service obligations and restrictive operating and financial covenants from incurring additional indebtedness.
- Inability to successfully identify, acquire, or effectively integrate and operate additional businesses.
- Uncertainty around the performance of current businesses and ability to maintain the business model and improve capital efficiency.
- Challenges in effectively managing business growth and maintaining profitability.
- Competitive environment in which businesses operate.
- Trends and regulatory environment in the industries of operation.
- Changes in general economic or business conditions, including interest rates and inflation.
- Ability to retain or replace qualified employees.
- Potential for labor disputes, strikes, or other employee grievances.
- Risks of casualties, condemnation, or catastrophic failures at business facilities.
- Costs and effects of legal and administrative proceedings, settlements, investigations, and claims.
Future Outlook
Management believes current working capital and expected additional financing should be sufficient for at least one year, but additional funds from new financing and/or future equity raises are required for continued operations and to execute the business plan, particularly for new acquisitions. The company aims to raise between $5 million to $10 million for acquisitions, with the amount dependent on sellers' willingness to accept seller notes or equity. There is no assurance that sufficient capital will be obtained or that the company will operate profitably in the future.
Management Comments
- Management is in continuous discussions with prospective investors and believes the raising of capital will allow the company to fund its cash flow shortfalls and pursue new acquisitions.
- We monitor outstanding cases as they develop through ongoing discussions with attorneys, doctors and our third-party medical billing company and additionally monitor our settlement realization rates over time.
- We currently have one primary method of accelerating our cash settlement of our revenue and related accounts receivable through accepting lower settlement amounts during the final negotiations of the settlement, which is coordinated through our third-party medical billing company.
Industry Context
Cardiff Lexington operates primarily in the healthcare industry through its Nova Ortho and Spine, LLC subsidiary, providing diagnostic and surgical services for traumatic injury victims, focusing on lien-based medical services. It also has a real estate segment, Edge View Properties, Inc., which owns land intended for residential development. The healthcare segment's revenue model relies on insurance settlements, which can involve prolonged negotiations and variable realization rates. The company's strategy is to acquire undervalued and undercapitalized companies, primarily in healthcare, and provide them with capitalization and leadership.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Accounting Officer | Zia Choe | NA | 2024-01-31 | Zia Choe was the 'former' Chief Accounting Officer as of January 31, 2024, implying a departure or change in role, though no new person is explicitly named in the filing for this role. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses | Identified material weaknesses in internal control over financial reporting, specifically related to interest expense-related cash flow classification and credit loss expense reclassification. | 2025-06-30 | Disclosure controls and procedures were not effective. Remediation efforts are ongoing, including strategic hiring, training, documentation procedures, and enhancing review processes for cash flow statements. |
Legal Proceedings
- The company may become involved in various lawsuits and legal proceedings in the ordinary course of business.
- Management is not currently aware of any legal proceedings or claims that are believed to have a material adverse effect on the company's business, financial condition, or operating results.
Related Party Transactions
- Amounts due from previous owners who are current managers of Edge View Properties, Inc. totaling $4,979 as of June 30, 2025 and December 31, 2024.
- Short-term advances of $120,997 from the Chairman of the Board were fully repaid during the six months ended June 30, 2024.
- A twelve-month convertible promissory note in the principal amount of $5,000 was issued to the CEO on August 25, 2023, which was paid in full in August 2024.
- Accrued compensation for Alex Cunningham (CEO) totaled $2,215,500 as of June 30, 2025, with interest accrued at 5% per annum on past due amounts.
- Accrued compensation for Daniel Thompson (Chairman) totaled $2,320,500 as of June 30, 2025, with interest accrued at 5% per annum on past due amounts.
Stakeholder Impact
- Shareholders face significant dilution risk from potential future equity raises and continued losses, impacting shareholder equity.
- Employees, particularly management, have compensation structures that include potential for promissory notes if cash payment is not feasible, and performance bonuses tied to company milestones.
- Creditors, especially those holding the line of credit and convertible notes, are exposed to increased financial risk given the company's rising debt, high interest expenses, and going concern warning.
- Customers (patients in the healthcare segment) are indirectly impacted by the company's financial stability, though the lien-based model aims to ensure payment for services.
Next Steps
- Raise additional capital through debt or equity financings to fund operations and pursue new acquisitions.
- Continue efforts to accelerate cash settlement of accounts receivable, potentially by accepting lower settlement amounts.
- Evaluate and update estimates of settlement realization rates quarterly based on a trailing 24-month historical review.
- Implement and reinforce remedial procedures to address material weaknesses in internal control over financial reporting, including strategic hiring, training, proper documentation, and enhanced review processes.
- Develop vacant land in Salmon, Idaho, into a residential community, potentially through a joint venture agreement with a developer.
Key Dates
| Date | Description |
|---|---|
| 2009-03-12 | Company issued a debenture in the principal amount of $20,000. |
| 2014-07-16 | Acquisition of Edge View Properties, Inc. (real estate segment). |
| 2017-01-24 | Company issued convertible promissory note (Note 10) in the principal amount of $80,000. |
| 2020-06-02 | Company obtained an SBA loan in the principal amount of $150,000. |
| 2021-05-31 | Acquisition of Nova Ortho and Spine, LLC (healthcare segment). |
| 2023-03-30 | Company executed a third tranche under Note 10 in the principal amount of $25,000 (Note 10-2). |
| 2023-08-11 | Company executed a fourth tranche under Note 10 in the principal amount of $25,000 (Note 10-3). |
| 2023-09-29 | Company and Nova entered into a two-year revolving purchase and security agreement with DML HC Series, LLC. |
| 2024-01-02 | Company entered into an employment agreement with Matthew T. Shafer, Chief Financial Officer. |
| 2024-01-09 | Company effected a 1-for-75,000 reverse split of its outstanding common stock. |
| 2024-01-19 | Company issued 62,500 shares of Series I preferred stock to Daniel R. Thompson (Chairman) and Alex Cunningham (CEO) for bonus compensation. |
| 2024-01-31 | Company issued 5,000 shares of Series I preferred stock to Matthew Shafer (CFO) and 2,500 shares to Zia Choe (former Chief Accounting Officer). |
| 2024-02-04 | Company issued 37,104 shares of common stock as part of the Red Rock settlement. |
| 2024-03-05 | Company issued 7,500 shares of common stock to an investor relation service provider. |
| 2024-03-26 | Company issued 30,000 shares of common stock to three board members. |
| 2024-04-11 | Company issued 938,908 shares of Series Y senior convertible preferred stock in exchange for settlement of Notes 40-1 to 40-10. |
| 2024-04-24 | Amendment No. 1 to the DML revolving purchase and security agreement increased the maximum advance amount to $8,000,000. |
| 2024-05-01 | Total outstanding principal and interest on Note 9 and Note 10-1 were paid in full. |
| 2024-06-11 | Company entered into a settlement agreement and release of claims with the holder of Series R convertible preferred stock and certain convertible promissory notes, cancelling them for a new promissory note of $535,000. |
| 2024-06-11 | Amendment No. 2 to the DML revolving purchase and security agreement further increased the maximum advance amount to $11,000,000. |
| 2024-08-15 | Deadline for the planned underwritten public offering, after which different payment terms for a promissory note apply. |
| 2024-12-27 | Amendment No. 3 to the DML revolving purchase and security agreement further increased the maximum advance amount to $15,000,000. |
| 2025-01-01 | Alex Cunningham's employment agreement became effective, and Daniel Thompson's employment agreement was amended. |
| 2025-06-30 | End of the second fiscal quarter for 2025. |
| 2025-06-30 | Company issued 15,000 shares of common stock to an investor relation service provider. |
| 2025-06-30 | Company retired 59,248 shares of common stock as part of a legal settlement. |
| 2025-08-18 | Date of common stock outstanding count. |
| 2025-08-19 | Filing date of the 10-Q report. |
Recommendation
strong sellThe filing reveals a company in a precarious financial position. Despite revenue growth, the net loss has dramatically increased, driven by an unsustainable surge in interest expense. The cash balance has significantly declined, and the company explicitly states 'substantial doubt about its ability to continue as a going concern.' This indicates severe liquidity issues and a high risk of financial distress or even cessation of operations if significant capital cannot be raised on favorable terms. The increasing reliance on a line of credit and the accumulated deficit further underscore the fundamental financial instability. For a seasoned investor, these factors present an unacceptable level of risk, warranting a strong sell recommendation to avoid further capital erosion.
Keywords
Cardiff Lexington, CDIF, 10-Q, Quarterly Report, Healthcare, Medical Services, Real Estate, Financial Results, SEC Filing, Convertible Preferred Stock, Debt, Liquidity, Going Concern, Revenue, Net Loss, Interest Expense, Accounts Receivable
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.